SERINC5 restricts influenza virus infectivity

PLoS Pathog. 2022 Oct 12;18(10):e1010907. doi: 10.1371/journal.ppat.1010907. eCollection 2022 Oct.


SERINC5 is a multi-span transmembrane protein that is incorporated into HIV-1 particles in producing cells and inhibits HIV-1 entry. Multiple retroviruses like HIV-1, equine infectious anemia virus and murine leukemia virus are subject to SERINC5 inhibition, while HIV-1 pseudotyped with envelope glycoproteins of vesicular stomatitis virus and Ebola virus are resistant to SERINC5. The antiviral spectrum and the underlying mechanisms of SERINC5 restriction are not completely understood. Here we show that SERINC5 inhibits influenza A virus infection by targeting virus-cell membrane fusion at an early step of infection. Further results show that different influenza hemagglutinin (HA) subtypes exhibit diverse sensitivities to SERINC5 restriction. Analysis of the amino acid sequences of influenza HA1 strains indicates that HA glycosylation sites correlate with the sensitivity of influenza HA to SERINC5, and the inhibitory effect of SERINC5 was lost when certain HA glycosylation sites were mutated. Our study not only expands the antiviral spectrum of SERINC5, but also reveals the role of viral envelope glycosylation in resisting SERINC5 restriction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / metabolism
  • Glycoproteins / metabolism
  • HIV-1* / physiology
  • Hemagglutinins / metabolism
  • Humans
  • Influenza, Human*
  • Mice
  • Orthomyxoviridae* / metabolism
  • nef Gene Products, Human Immunodeficiency Virus / metabolism


  • nef Gene Products, Human Immunodeficiency Virus
  • Hemagglutinins
  • Antiviral Agents
  • Glycoproteins